Physician profile
Stuart G Schultz
NPI 1134160427
$1,019.62
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $239 · 2021: $308 · 2022: $39.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $480.01 | 2019-2022 | |
| Therapeuticsmd, INC. | $70.93 | 2019 | |
| Merck Sharp & Dohme LLC | $64.73 | 2019-2021 | |
| Pfizer INC. | $64.66 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $52.42 | 2020-2021 | |
| Millicent US INC | $43.35 | 2019-2020 | |
| Lupin INC. | $38.92 | 2019 | |
| Avion Pharmaceuticals | $36.32 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $35.81 | 2019-2020 | |
| Hologic Sales and Service, LLC | $25.53 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $17.67 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.03 | 2019 | |
| Agile Therapeutics, INC. | $15.77 | 2021 | |
| Myovant Sciences INC. | $14.97 | 2021 | |
| Evofem Biosciences, INC. | $14.97 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $14.78 | 2019 | |
| Duchesnay USA Incorporated | $12.75 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.